Jan 31, 2020
Lilly's REYVOW(TM) (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription
Aug 26, 2019
Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Jul 13, 2019
Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study
Jul 12, 2019
AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality® (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migraine
May 21, 2019
Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions
May 08, 2019
AAN 2019: Two New Analyses of Lasmiditan Phase 3 Studies Measured Onset of Effect and the Effect of Lasmiditan in Patients with Prior Triptan Experience
Feb 04, 2019
Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
Dec 13, 2018
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Sep 10, 2018
Lilly to Showcase New Data at the 27th European Academy of Dermatology and Venereology (EADV) Congress, Furthering Innovation for Patients with Complex Dermatological Conditions
Jun 01, 2018
Lilly to Showcase New Data at Digestive Disease Week 2018 for Mirikizumab in Moderate-to-Severe Ulcerative Colitis
Apr 24, 2018
AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies